Abiopharma

🔍 Rodman David Malcom (Executive)

Company: Mineralys Therapeutics, Inc. (MLYS)

Report Date: 2026-02-12

Detailed Transactions and Holdings:

• Acquired 6,349 shares of Common Stock at $1.08 per share (Direct)
  Date: 2026-02-12 | Code: M | equity_swap_involved: 0 | shares_owned_after: 56,786.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 5,828 shares of Common Stock at $28.9353 per share (Direct)
  Date: 2026-02-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 50,958.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 521 shares of Common Stock at $29.6387 per share (Direct)
  Date: 2026-02-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 50,437.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Acquired 3,541 shares of Common Stock at $10.2 per share (Direct)
  Date: 2026-02-13 | Code: M | equity_swap_involved: 0 | shares_owned_after: 53,978.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,541 shares of Common Stock at $27.33 per share (Direct)
  Date: 2026-02-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 50,437.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 4,166 shares of Common Stock at $14.25 per share (Direct)
  Date: 2026-02-13 | Code: M | equity_swap_involved: 0 | shares_owned_after: 54,603.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 4,166 shares of Common Stock at $27.33 per share (Direct)
  Date: 2026-02-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 50,437.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 6,348 shares of Common Stock at $27.5835 per share (Direct)
  Date: 2026-02-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 44,089.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 6,349 shares of Stock Option at $1.08 per share (Derivative)
  Date: 2026-02-12 | Code: M | Expires: 2032-07-11 | equity_swap_involved: 0 | shares_owned_after: 31,743.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 3,541 shares of Stock Option at $10.2 per share (Derivative)
  Date: 2026-02-13 | Code: M | Expires: 2035-02-13 | equity_swap_involved: 0 | shares_owned_after: 127,501.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 4,166 shares of Stock Option at $14.25 per share (Derivative)
  Date: 2026-02-13 | Code: M | Expires: 2034-02-13 | equity_swap_involved: 0 | shares_owned_after: 100,001.00 | transaction_form_type: 4 | Footnotes: F1, F5

Footnotes:

• F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
• F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.5200 to $29.4200. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
• F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.5870 to $29.6600. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
• F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.3300 to $28.0000. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
• F5: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.
• F6: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant.